Paul Eder
Psychiatry · New York, NYNPI 1104074020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Gilead at 42.5% of the total. 2025 is the largest year on record at $331, more than ten times the $17 reported in 2019.
Across 9 payments — averaging $51.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$196
- E.r. Squibb & Sons, L.L.C.$135
- Viiv Healthcare Company$112
- Alkermes, Inc.$17
Across 169 payments — averaging $17,462 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$994K
- Janssen Research & Development, LLC$726K
- Pfizer$384K
- Biohaven Pharmaceuticals, Inc.$306K
- Sage Therapeutics, LLC$228K
- AbbVie$202K
- plus $110K from 1 others
What the payments were for
- Food & beverage$461100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $196 |
| E.r. Squibb & Sons, L.L.C. | 1 | $135 |
| Viiv Healthcare Company | 4 | $112 |
| Alkermes, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$135
How this compares
$461 in reported general payments places this provider in the 70th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 27 | $81,111 |
| Chlorpromazine Hcl | 26 | $3,319 |
| Haloperidol Decanoate | 23 | $1,379 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $1,292 |
| Divalproex Sodium | 22 | $489 |
| Benztropine Mesylate | 34 | $414 |
| Olanzapine | 34 | $400 |
| Quetiapine Fumarate | 40 | $367 |
| AmantadineAmantadine Hcl | 11 | $355 |
| Mirtazapine | 35 | $273 |
| Aripiprazole | 12 | $230 |
| Risperidone | 37 | $169 |
| Bupropion XlBupropion Hcl | 14 | $168 |
| Trazodone Hcl | 27 | $130 |
| Sertraline Hcl | 28 | $107 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.